Quick versus Quantitative: Evaluation of Two Commercial Real-Time PCR Assays for the Detection of Pneumocystis jirovecii from Bronchoalveolar Lavage Fluids

Pneumonia, caused by the opportunistic fungus Pneumocystis jirovecii, poses a significant risk for immunocompromised individuals. Laboratory testing for P. jirovecii is progressively shifting toward the use of molecular tests such as real-time PCR; however, this is often performed at reference laboratories. ABSTRACT Two commercial real-time PCR assays for the detection of Pneumocystis jirovecii were compared, the quantitative RealStar P. jirovecii assay and the qualitative DiaSorin P. jirovecii assay, the latter of which can be used without nucleic acid extraction. Archived bronchoalveolar lavage (BAL) specimens (n = 66), previously tested by molecular methods, were tested by both assays, and the results were compared to the respective original result. The RealStar P. jirovecii assay demonstrated good positive percent agreement (PPA) (90% [95% confidence interval (CI), 72 to 97%]; 27/30) and negative percent agreement (NPA) (100% [95% CI, 88 to 100%]; 36/36) with the reference method. The DiaSorin P. jirovecii assay concordantly detected P. jirovecii in 19 of 24 positive BAL samples (PPA = 73% [95% CI, 52 to 88%]). All negative BAL samples gave concordant results (NPA = 100% [95% CI, 87 to 100%]; 34/34). Discordant results occurred mostly in samples with low fungal loads. In conclusion, the RealStar assay demonstrated good concordance with reference results, and the DiaSorin P. jirovecii assay performed well for negative BAL and positive BAL samples with P. jirovecii concentrations of greater than 260 copies/mL. IMPORTANCE Pneumonia, caused by the opportunistic fungus Pneumocystis jirovecii, poses a significant risk for immunocompromised individuals. Laboratory testing for P. jirovecii is progressively shifting toward the use of molecular tests such as real-time PCR; however, this is often performed at reference laboratories. Many frontline laboratories are looking into improving their service and reducing turnaround times for obtaining P. jirovecii results by bringing molecular P. jirovecii testing in-house. We evaluated and compared two commercial real-time PCR assays with different workflows for the detection of P. jirovecii from bronchoalveolar lavage specimens. The RealStar P. jirovecii assay requires nucleic acid extraction and provides a quantification of fungal load for positive samples. The DiaSorin P. jirovecii assay offers a simple workflow without nucleic extraction from patient samples and qualitative results. Results from this study provide valuable information on performance and workflow considerations for laboratories that wish to implement P. jirovecii molecular testing.

[1]  J. Fishman,et al.  The Pathogenesis and Diagnosis of Pneumocystis jiroveci Pneumonia , 2022, Journal of fungi.

[2]  G. Benard,et al.  Performance of a Real Time PCR for Pneumocystis jirovecii Identification in Induced Sputum of AIDS Patients: Differentiation between Pneumonia and Colonization , 2022, Journal of fungi.

[3]  E. Burd,et al.  Clinical Utilization of DiaSorin Molecular Polymerase Chain Reaction in Pneumocystis Pneumonia , 2022, Open forum infectious diseases.

[4]  E. V. van Hannen,et al.  Comparison of the PneumoGenius® and RealStar® Pneumocystis jirovecii PCR CE-IVD assays with a lab developed test for the detection of Pneumocystis jirovecii. , 2021, Medical mycology.

[5]  Monrat Chulanetra,et al.  Quantitative PCR to Discriminate Between Pneumocystis Pneumonia and Colonization in HIV and Non-HIV Immunocompromised Patients , 2021, Frontiers in Microbiology.

[6]  C. Lechiche,et al.  Performance of the RealStar® Pneumocystis jirovecii PCR kit for the diagnosis of Pneumocystis pneumonia , 2021, Mycoses.

[7]  B. Åsvold,et al.  Semiquantitative Real-Time PCR to Distinguish Pneumocystis Pneumonia from Colonization in a Heterogeneous Population of HIV-Negative Immunocompromised Patients , 2021, Microbiology spectrum.

[8]  P. Boan,et al.  Quantitative Pneumocystis jirovecii real-time PCR to differentiate disease from colonisation. , 2021, Pathology.

[9]  H. Masur,et al.  Pneumocystis jirovecii Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  J. Buer,et al.  Evaluation of a commercial Loop‐mediated Isothermal Amplification (LAMP) assay for rapid detection of Pneumocystis jirovecii , 2020, Mycoses.

[11]  K. Mühlethaler,et al.  Is real time PCR preferable to the direct immunofluorescence in the diagnosis of Pneumocystis jirovecii pneumonia in HIV-infected patients? , 2020, BMC Research Notes.

[12]  P. Hauser,et al.  Ability of quantitative PCR to discriminate Pneumocystis jirovecii pneumonia from colonization , 2020, Journal of medical microbiology.

[13]  J. Stringer Pneumocystis. , 2020, International journal of medical microbiology : IJMM.

[14]  A. Kilic,et al.  Evaluation of the performance of DiaSorin molecular Pneumocystis jirovecii-CMV multiplex real-time PCR assay from bronchoalveolar lavage samples , 2020, Journal de Mycologie Médicale.

[15]  W. Melchers,et al.  The Fungal PCR Initiative's evaluation of in-house and commercial Pneumocystis jirovecii qPCR assays: Toward a standard for a diagnostics assay. , 2019, Medical mycology.

[16]  C. Ki,et al.  Comparative Evaluation Between the RealStar Pneumocystis jirovecii PCR Kit and the AmpliSens Pneumocystis jirovecii (carinii)-FRT PCR Kit for Detecting P. jirovecii in Non-HIV Immunocompromised Patients , 2018, Annals of laboratory medicine.

[17]  P. Zunic,et al.  Evaluation of quantitative FTD-Pneumocystis jirovecii kit for Pneumocystis infection diagnosis. , 2017, Diagnostic microbiology and infectious disease.

[18]  G. Procop,et al.  Pneumocystis PCR: It Is Time to Make PCR the Test of Choice , 2017, Open forum infectious diseases.

[19]  H. Einsele,et al.  Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. , 2016, The Journal of antimicrobial chemotherapy.

[20]  M. Gari-Toussaint,et al.  Detection of Pneumocystis jirovecii by Quantitative PCR To Differentiate Colonization and Pneumonia in Immunocompromised HIV-Positive and HIV-Negative Patients , 2016, Journal of Clinical Microbiology.

[21]  A. Hendrich,et al.  Pneumocystis jirovecii—from a commensal to pathogen: clinical and diagnostic review , 2015, Parasitology Research.

[22]  A. Morris,et al.  Colonization by Pneumocystis jirovecii and Its Role in Disease , 2012, Clinical Microbiology Reviews.

[23]  John W. Wilson,et al.  Pneumocystis jirovecii testing by real-time polymerase chain reaction and direct examination among immunocompetent and immunosuppressed patient groups and correlation to disease specificity. , 2011, Diagnostic microbiology and infectious disease.

[24]  S. Balajee,et al.  Pneumocystis Jirovecii Pneumonia: Current Knowledge and Outstanding Public Health Issues , 2010 .

[25]  Alimuddin Zumla Mandell, Douglas, and Bennett's principles and practice of infectious diseases , 2010, The Lancet Infectious Diseases.

[26]  A. Limper,et al.  Current insights into the biology and pathogenesis of Pneumocystis pneumonia , 2007, Nature Reviews Microbiology.

[27]  E. Calderón,et al.  Pneumocystis jirovecii in General Population , 2005, Emerging infectious diseases.

[28]  S. Ferrer,et al.  High seroprevalence of Pneumocystis infection in Spanish children. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  Michael L Wilson,et al.  Detection of Pneumocystis jiroveci in Respiratory Specimens by Four Staining Methods , 2004, Journal of Clinical Microbiology.

[30]  C. Cabrera,et al.  Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  W. Hughes,et al.  Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. , 1978, Pediatrics.

[32]  D. Church,et al.  Development and validation of a Pneumocystis jirovecii real-time polymerase chain reaction assay for diagnosis of Pneumocystis pneumonia , 2015, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[33]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[34]  M Tubiana,et al.  The European Organization for Research and Treatment of Cancer (EORTC). , 1988, International journal of radiation oncology, biology, physics.